Podcasts about ca19

In dieser Folge besprechen wir anhand einer Studie aus Göttingen die Relevanz von CA 19-9 in der Nachsorge des Pankreaskarzinoms. In einer Test- und Validierungsgruppe konnte hier eine verlässliche Rezidivvorhersage teils lange vor der Korrelation in der Bildgebung nachgewiesen werden. Moderation: Sophie Heisler Gast: Dr. med. Felix Rühlmann Besprochene Publikation: Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, Kleiß M, Leha A, Ghadimi M, Gaedcke J. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep. 2020 Jan 28;10(1):1332. doi: 10.1038/s41598-020-57930-x. PMID: 31992753; PMCID: PMC6987233.

Dr Charlie Andrews talks to Dr John Leeds. John Leeds is a Consultant Pancreaticobiliary Physician and Endoscopist based at the Freeman Hospital in Newcastle and an Honorary Clinical Senior Lecturer based in the Population Health Sciences Institute at Newcastle University. He is involved in research in pancreaticobiliary disorders including benign and malignant conditions as well as outcomes from therapeutic/advanced endoscopy.John is a member of the British Society of Gastroenterology and Pancreatic Society of Great Britain and Ireland. He serves on the endoscopy and Pancreas committees for BSG and is the website lead for PSGBI.He is also a founder member of the BSG Pancreas Clinical Research Group which is coordinating research for the society.Key Learnings from this episode:Challenges in Early Detection of Pancreatic Cancer • Pancreatic cancer is often diagnosed at an advanced stage due to the deep location of the pancreas and the lack of early symptoms. • Tumors in the body and tail of the pancreas can grow significantly before causing symptoms, often invading major arteries or veins, making them inoperable. • Tumors in the head of the pancreas may present earlier due to bile duct obstruction, leading to jaundice, but even these are often detected late. Early Symptoms and Red Flags • Early symptoms are vague or absent, making early diagnosis difficult. • Possible early indicators include: • Weight loss (often a sign of advanced disease). • New-onset diabetes, particularly in individuals with a normal BMI or without typical risk factors for type 2 diabetes. • Jaundice, which is a significant red flag and often indicates a serious underlying condition. • Classic signs like painless jaundice and Courvoisier's sign (palpable gallbladder) are important but not always present. Limitations of Current Screening Methods • There is no reliable biomarker or screening test for pancreatic cancer: • CA19-9 is not suitable as a screening tool due to its lack of specificity (elevated in other conditions). • Imaging techniques like CT scans or MRIs are used but have limitations, including incidental findings that may lead to unnecessary anxiety (“scanxiety”) and over-investigation. • Screening is currently limited to high-risk groups, such as those with familial pancreatic cancer syndromes or hereditary pancreatitis. High-Risk Groups for Screening • Familial pancreatic cancer accounts for less than 10% of cases. Criteria for screening include: • Multiple family members with pancreatic cancer, especially diagnosed under age 50–60. • Genetic syndromes like BRCA mutations, familial adenomatous polyposis (FAP), and Peutz-Jeghers syndrome. • Hereditary pancreatitis patients have an increased risk but are harder to screen due to pre-existing pancreatic abnormalities. Emerging Research and Future Directions • Studies are exploring potential biomarkers, such as microbiome signatures in the pancreas, which might help identify high-risk individuals in the future. • Trials like the EuroPAC study focus on surveillance protocols for high-risk individuals using imaging techniques like MRI or endoscopic ultrasound. • Research into new-onset diabetes as a potential marker for pancreatic cancer is ongoing but currently has a low yield due to the high prevalence of type 2 diabetes unrelated to malignancy. Considerations for Screening and Surveillance • Screening should be carefully targeted to avoid over-diagnosis and unnecessary investigations. • The psychological impact of screening (e.g., anxiety from incidental findings) must be considered. • Smoking cessation is emphasized as smoking is a significant risk factor for pancreatic cancer. Advances in Treatment Approaches • PET-CT scans are increasingly used to detect systemic disease that might not be evident on standard CT scans. • Neoadjuvant treatments (therapy before surgery) are being... Chapters (00:00:00) - Ingest(00:00:53) - Pancreatic Cancer(00:04:03) - New diabetes and pancreatic cancer(00:08:01) - Pancreatic Cancer: Screening(00:15:42) - Determining breast cancer early is hard(00:16:03) - Pulmonary neuroendocrine tumors of the pancreas(00:22:26) - Pancreatic cancer 20, Management(00:29:00) - Pancreatic cancer, management principles(00:33:48) - Primary Care Take Home: Pancreas, pain(00:40:29) - Primary Care: Pancreas Cancer Episode 2

BUFFALO, NY- June 19, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 13, 2024, entitled, “Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management.” Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. In this new study, researchers Scott Strum, Mark Vincent, Meghan Gipson, Eric McArthur, and Daniel Breadner from the Schulich School of Medicine and Dentistry, London Health Sciences Centre, and Royal College of Surgeons in Ireland analyzed whether three tumor markers (CEA, CA19-9, and CA-125) held associations with radiographic and clinical outcomes in NSCLC. “The aim of this retrospective study was to provide additional evidence for the clinical use of conventional serum tumor markers CEA, CA19-9, and CA-125 in NSCLC management.” It constituted a single-center study of NSCLC patients treated with systemic therapy at the London Regional Cancer Program. Serum tumor markers were analyzed for differences in radiographic responses (RECIST v1.1 or iRECIST), associations with clinical characteristics, and all-cause mortality. A total of 533 NSCLC patients were screened, of which 165 met inclusion criteria. A subset of 92 patients had paired tumor markers and radiographic scans. From the latter population, median (IQR) fold-change from nadir to progression was 2.13 (IQR 1.24–3.02; p < 0.001) for CEA, 1.46 (IQR 1.13–2.18; p < 0.001) for CA19-9, and 1.53 (IQR 0.96–2.12; p < 0.001) for CA-125. Median (IQR) fold-change from baseline to radiographic response was 0.50 (IQR 0.27, 0.95; p < 0.001) for CEA, 1.08 (IQR 0.74, 1.61; p = 0.99) for CA19-9, and 0.47 (IQR 0.18, 1.26; p = 0.008) for CA-125. “In conclusion, tumor markers are positioned to be used as adjunct tools in clinical decision making, especially for their associations with radiographic response (CEA/CA-125) or progression (CEA/CA-125/CA-19-9).” DOI - https://doi.org/10.18632/oncotarget.28566 Correspondence to - Daniel Breadner - daniel.breadner@lhsc.on.ca Video short - https://www.youtube.com/watch?v=8LO-Hn0fbrg Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28566 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, tumor marker, biomarker, lung cancer; NSCLC, translational research About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Qu'est-ce qui se passe quand 3 fans de la franchise Harry Potter se retrouvent autour d'un Similo sur le susmentionné thème ? Similo - Harry Potter Par Hjalmar Hach, Martino Chiacchiera & Pierluca Zizzi Illustré par Naïade Édité par Gigamic & Horrible Guild De 2 à 8 joueuses Pour 7 ans et + Pour environ 10 minutes Description : Cet opus du jeu de déduction Similo, encensé par la critique, prend place dans le Wizarding World. Les fans de la saga tentent de deviner un personnage secret parmi les 12 révélés, tous issus de l'univers Harry Potter. Emission présentée par Alex & Bar Loufoque,& Zephiriel Générique par Adrien Larouzée Twitter @ledefausse Instagram Le Dé Faussé Facebook Le Dé Faussé Envie de nous soutenir ? Vous pouvez, si vous le souhaitez, grâce au Patreon de notre collectif, le Vaisseau Hyper Sensas ! patreon.com/vaisseauhypersensas Découvrez également notre site vaisseauhypersensas.fr Rejoignez nous sur Discord! https://discord.gg/uGxNp6n

Rick Greene, MD, discusses with Susan Tsai, MD, MHS, the results of an analysis examining the efficacy of second-line gemcitabine/nab-paclitaxel (GnP) after first-line FOLFIRINOX in the neoadjuvant setting among patients with operable pancreatic cancer who were treated with a total neoadjuvant approach. Dr. Tsai is the senior author of, “CA19-9 Response to First-line Neoadjuvant FOLFIRINOX and Second-line Gemcitabine/nab- Paclitaxel in Patients with Operable Pancreatic Cancer.” Dr. Tsai is Professor of Surgery and Chief of the Division of Surgical Oncology at The Ohio State University Comprehensive Cancer Center, Columbus, OH.

#TSGMultimediaPodcast #HistoricPreservation #ModelRailroading #Trains #RailroadsThis month's TSG Podcast includes::38 Welcome1:04 SBHRS4:19 Rail Fair at Ardenwood Historic Farm14:27 Catching The Amtrak Coast Starlight in Coyote, CA16:53 Catching The Amtrak Coast Starlight in Santa Clara, CA19:02 N Scale Pacific Electric Steeple Cab with Robin Gilstrom20:38 Talking Trains21:22 Op Session - Ops at The Rawhide & Duct Tape25:49 Gratuitous Women In Model Railroading SIG plug30:34 Railfanning Watsonville Junction32:50 NMRA-PCR Coast Division Meet at the Santa Clara Depot35:03 Op Session - Paul Weiss's Central Vermont37:38 Another Gratuitous Women In Model Railroading SIG plug with Special Guest Bob Hanmer42:26 Upcoming Event SBHRS Fall Open House46:28 Catches Of The Month47:35 Fans Of Talking Trains On Facebook47:51 TSG Train Crew / ConclusionHere are some of the ways you can support the content you love:https://www.patreon.com/TSGMultimediahttps://www.paypal.com/paypalme/tsgmultimediahttps://tsgmultimedia.com/shop/https://tsg-multimedia-swag.creator-spring.com/Please share: If you enjoy this content, please hit the "like" button and share it with your friends on social media!You can join TSG Multimedia on these other social media channels:FaceBook: https://www.facebook.com/tsgmultimediafaceInstagram: https://www.instagram.com/tsg_multimedia/Twitter: http://www.twitter.com/TSGMultimedia©2023 TSG Multimedia. All Rights Reserved.

Dr Ahsen Ustaoglu interviews Dr Iris Levink on her study investigating the additive value of CA19.9 monitoring in a pancreatic cyst surveillance program, part of the PACYFIC-trial (www.pacyfic.net).

Dr Mike Hudson, CEO of EDX Medical Group #EDX discusses their collaboration with Tianjin Bioscience Diagnostic Technology Co. Ltd which will accelerate access to highly reliable, affordable tests for a range of cancers in the UK & Europe. Highlights The programme is a result of a partnership between the Company and Tianjin Bioscience Diagnostic Technology Co. Ltd ("Bioscience"), an internationally active, ISO 13485-certified research-based manufacturer of diagnostic products and reagents. The Company has been selected by Bioscience as its lead partner to validate and commercialise its suite of internationally recognised cancer biomarkers in Europe. The programme will encompass the validation and clinical deployment of Bioscience's digital chemiluminescence immunoassay technology for an initial 10 cancer biomarkers, including the key glycoprotein Carbohydrate Antigens: CA-15-3, CA19-9, CA-125, and CA-72-4. These biomarkers are recognised as important tools to improve the clinical management of a range of cancers and will be deployed both individually and in combination using the Bioscience automated analysers. To read the full RNS click here

In this episode Annemie Steyn and Nicollete Kock find out about commonly used tumour markers in general surgery. From CEA, CA19-9 to AFP, calcitonin, and chromogranin Prof Brand gives a broad overview of when and how we should use these tumour markers. Stanleur Capital: Medical practice and personal financial solutions

In this episode Annemie Steyn and Nicollete Kock find out about commonly used tumour markers in general surgery. From CEA, CA19-9 to AFP, calcitonin, and chromogranin Prof Brand gives a broad overview of when and how we should use these tumour markers.

IGSTS Episode #16I got somethang ta say That justice is a blind goddessIs a thing to which we poor are wiseHer bandage hides two festering soresThat once, perhaps, were eyesThe Great Langston HughesDaunte Wright's murder. Was it a careless mistake or something more sinister? SAF Moe ur Prison Lawyer and Ron B in the Middle discuss the facts from their perspectives. Moreover, the hosts of I got somethang ta say, try to make sense of a verdict, that makes no sense. Under the current system of law enforcement, if a police officer is in the process of apprehending an individual for some alleged offense, that person has no right to resist. Even if the officer is in the wrong. That individual cannot use deadly force against the aggressor, however, it can and will be used against that individual. As most Americans are not overt victims of overseeing and control, a problem only faced by the most downtrodden, critical subjects such as the Potter verdict, over-policing, and hyper-minority incarceration may seem overly sensationalized, notwithstanding, as for African Americans who deal with it on a day-to-day basis, it is only the system reaffirming its grasp around their proverbial throats. The subject of unarmed men and women of color being murdered is a very sensitive topic; moreover, faced with the fact that law enforcement has been used as a tool to remove all human dignity from certain persons for the purpose of control, this conversation must be had, this space must be free and open until no person is killed simply for being unapologetically different in America!Justin Terrell (Executive Director) Minnesota Justice Research Center is our special guest and speaks truth to power. Mr. Terrell is a lifelong advocate for justice and he discusses politics in Minnesota and felons' disenfranchisement in the political process.Note:In Tennessee v. Garner (1985), thus. Supreme Court reframed such actions by police to fall under the Fourth Amendment. The Court commented that "Whenever an officer restrains the freedom of a person to walk away, he has seized that person . . . there can be no question that application of deadly force is a seizure subject to the reasonableness requirement of the Fourth Amendment." This case essentially abolished the over-broad use of the "fleeing felon" doctrine by striking down the use of "all necessary means" to apprehend fleeing suspects. This Episode 16 is dedicated to all humans who were murdered by police violence. Here are a few names:1. Tony McDade aka Natosha McDade, 38, Tallahassee, FL2. Modesto "Marrero Desto" Reyes, 35, Marrero, LA3. Ruben Smith III, 35, North Little Rock, AK4. Jarvis Sullivan, 44, Yulee, FL5. Terrell Mitchell, 34, Philadelphia, PA6. Momodou Lamin Sisay, 34, Snellville, GA7. Derrick Thompson, 46, Fountain, FL8. David McAtee, 53, Louisville, KY9. Tyquarn Graves, 33, Brooklyn, NY10. Kamal Flowers, 24, New Rochelle, NY11. Lewis Ruffin Jr., 38, Orlando, FL12. Phillip Jackson, 32, Tunnell Hill, GA13. Michael Blu Thomas, 63, Lancaster, CA14. Rayshard Brooks, 27, Atlanta, GA15. Cane Van Pelt, 23, Crown Pont, IN16. Donald Ward, 27, Phoenix, AZ17. Brandon Gardner, 24, Beach Park, IL18. Terron Jammal Boone, 31, Rosamond, CA19. Derrick Canada, 43, Giddings, TX20. Skyleur Toung, 31, San Bernardino, CA21. Robert D'Lon Harris, Vinita, OK22. Rasheed Mathew Moorman, 26, Roanoke, VA23. Aloysius Larue Keaton, 58, Little Rock, AK24. Kevin O. Ruffin, 32, Sheboygan, WI25. Ky Johnson, 31, Kansas City, MO26. William Wade Burgess III, 27, St. Louis, MO27. Joseph W. Denton, 35, Milwaukee, WI28. Paul Williams, Houston, TX29. Malik Canty, 36, Paterson, NJ30. Erroll Johnson, 31, Monroe, LA31. Richard Lewis Price, 49, San Diego, CA32. Hakim Littleton, 20, Detroit, MI33. Vincent Demario Truitt, 17, Austell, GA34. Aaron Anthony Hudson, 31, Syracuse, NY35. Darius Washington, 24, Chicago Heights, IL36. Vincent Harris, 51, Baton Rouge, LA37. Jeremy Southern, 22, Sacramento, CA38. Name withheld by police, Detroit, MI39. Chester Jenkins, 60, Stockton, CA40. David Earl Brooks Jr., 45, Roxboro, NC41. Darrien Walker, 28, Detroit, MI42. Ashton Broussard, 30, Houston, TX43. Amir Johnson, 30, Ventnor City, NJ44. Julian Edward Roosevelt Lewis, 60, Sylvania, GA45. Salaythis Melvin, 22, Orlando, FL46. Jonathan Jefferson, Bossier City, LA47. Rafael Jevon Minniefield, 29, Moreland, GA48. Kendrell Antron Watkins, 31, Tuscaloosa, AL49. Anthony McClain, 32, Pasadena, CA50. Adrian Jason Roberts, 37, Hope Mills, NC51. Trayford Pellerin, 31, Lafayette, LA

Ignite your heart and soul with Sara Troy and her guest Christina Hill with Athella Being alone and ok with oneself, the practice of solidarity, and keeping oneself aligned while in the midst of others (esp. men and wild egos!) https://selfdiscoverymedia.com/2019/10/28/ca19-43-being-alone-and-ok-with-oneself-with-christina-hill/

Calendrier de l'Avent Dé Faussé Feat bar Loufoque : Bazar Quest ! En 20 minutes on explore le jeu de cette semaine. Après une phase de présentation et une phase de jeu, il est temps de débriefer et de régler les comptes ! Bazar Quest Par Jonathan Ying Illustré par Victoria Ying Édité par Origames De 2 à 6 joueuses Pour 8 ans et + Pour 30 à 60 minutes Description : Bazar Quest, un jeu medfan épique d'arnaques et d'aventures! Tout doit disparaître ! Présenté par Bar Loufoque, Alex,Zephiriel & Sam Twitter @ledefausse Instagram Le Dé Faussé Facebook Le Dé Faussé

BioLanhee Chen is currently a candidate for Controller of California. After earning four degrees from Harvard University, including a law degree and doctorate in political science, he served in senior roles in both Republican and Democratic presidential administrations.Lanhee is regarded as one of America's leading policy commentators and experts - specifically on health care. He teaches at Stanford,  was unanimously confirmed by the United States Senate to serve as a member of the independent and bipartisan Social Security Advisory Board.Lanhee has also built his own small business, which focuses on providing advice on fiscal and other public policy issues to leaders in both the public and private sectors. He is an investor who works with entrepreneurs to help them grow their businesses and create new jobs. He is currently the Chair of the Board of Directors of El Camino Health, a health care system in his community. Times0:15 - Intro to Lanhee1:30 - What does the Controller of CA do & why is Lanhee running?5:15 - Focusing on state policy vs federal policy7:15 - $31 billion in unemployment insurance fraud16:00 - Conceptualizing how large $30 billion is for CA19:00 - Will CA see any of that money again?21:15 - Audit powers of the Controller25:15 - Medi-Cal & Medicaid32:00 - Major drivers of health care costs40:15 - Specifics of price transparency & cost45:45 - History of employment based health care & path dependence52:30 - Closing thoughts on the Golden State LinksLanhee's campaign websiteLanhee's twitterNarrativemonopoly.com

In 2019, a study published in Oncotarget showed a C. elegans cancer screening test could detect pancreatic tumors in mice. In 2021, a team of researchers from Osaka University and Hirotsu Bio Science Inc. sought to employ this clinical tactic in the context of early pancreatic cancer detection in humans. Their paper was published as the cover of Oncotarget's Volume 12, Issue, 17, and entitled, “Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer.” “Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest diseases, with a five-year survival rate of 9%.” In this study, 83 pancreatic cancer patients from clinics in Japan participated in an open-label pilot study. Participant age, sex, pathological progression, CA19-9 values, CEA values, and urine samples were collected. All data were entered into statistical analysis. Multiple concentrations and pre- and post-surgery urine were tested using the C. elegans scent test. The researchers used a well-established olfaction analysis method and simple system for observing chemotaxis called N-NOSE (Nematode-NOSE). The assayers placed the urine in two spots on one end of the assay plates and added sodium azide in two spots on both sides. The nematodes were placed in the center of the plates and observed for 30 minutes. The engaging behavior of C. elegans toward “favorite” smells suggested a positive chemotaxis index. The samples were assayed and analyzed to assess for the presence of positive peaks in average chemotaxis indices. They found that the C. elegans gravitated toward cancer-associated scents and that this chemotaxis index could be a sensitive marker to detect early-stage pancreatic cancer. “Given the success of the scent test in determining the presence of pancreatic cancer in patients with PDAC who showed various progressions before and after surgery, a blinded study was conducted to determine the ability of the scent test to distinguish between patients with early-stage PDAC and healthy volunteers […]” Full blog - https://www.oncotarget.org/2021/08/18/new-study-how-worms-can-detect-early-pancreatic-cancer/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28035 DOI - https://doi.org/10.18632/oncotarget.28035 Full text - https://www.oncotarget.com/article/28035/text/ Correspondence to - Hideshi Ishii - hishii@gesurg.med.osaka-u.ac.jp Keywords - Caenorhabditis elegans, early-stage pancreatic cancer, scent test, biomarker, diagnosis About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Listen to the latest oncology-focused research published in this week's issue of Oncotarget, Volume 12, Issue 17. https://www.oncotarget.com/archive/v12/i17/ Research Paper (Cover) - “Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer” https://doi.org/10.18632/oncotarget.28035 Research Paper - “The role of circulating miRNAs and CA19-9 in pancreatic cancer diagnosis” https://doi.org/10.18632/oncotarget.28038 Research Paper - “Diverse transcriptional regulation and functional effects revealed by CRISPR/Cas9-directed epigenetic editing” https://doi.org/10.18632/oncotarget.28037 Research Paper - “The protective role of Prolyl oligopeptidase (POP) inhibition in acute lung injury induced by intestinal ischemia-reperfusion” https://doi.org/10.18632/oncotarget.28041 Research Paper - “Quantitative difference of oral pathogen between individuals with gastric cancer and individuals without cancer” https://doi.org/10.18632/oncotarget.28034 Research Paper - “Exosomal and non-exosomal miRNA expression levels in patients with HCV-related cirrhosis and liver cancer” https://doi.org/10.18632/oncotarget.28036 Review- “Role of microRNAs in glioblastoma” https://doi.org/10.18632/oncotarget.28039 Editorial - “Mantle cell lymphoma patients in first relapse: we pretty much know what to do” https://doi.org/10.18632/oncotarget.27980 (PDF Download) Editorial - “UBE2T: A new molecular regulator of cancer stemness in hepatocellular carcinoma” https://doi.org/10.18632/oncotarget.28033 (PDF Download) Research Perspective - “Hypofractionation: less is more?” https://doi.org/10.18632/oncotarget.28023 Keywords - Caenorhabditis elegans, pancreatic cancer, microRNA, biomarkers, DNA methylation, acute lung injury (ALI), periodontal disease, gastric cancer, miRNA, liver cancer, glioblastoma, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Rick Greene, MD, and Melissa Hogg, MD, discuss the relationship of serum CA19-9 to other markers of response, and the related thresholds correlating to outcomes, following neoadjuvant therapy for pancreatic adenocarcinoma. Dr. Hogg is author of the article, “Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.” Dr. Hogg is the Director of HPB Surgery and Director of Robotic Training for Grainger Lab at the Northshore University Healthsystem, Chicago, IL.

It's Remfry's pick for the Classic Albums series and we're back to doubles due to lockdown, so Remfry's decided to cover alt. rock Gods Pixies. The Boston indie legends recorded Surfer Rosa in November 1987, just 11 months after Black Francis and Joey Santiago dropped out of the University of Massachusetts, Amherst to form the band. Bone Machine, River Euphrates, Gigantic and Where is my Mind? are all still beloved songs from the band's back catalogue. Steve and Remfry dive into the making of the record and the band's tumultuous relationship with producer Steve Albini. See acast.com/privacy for privacy and opt-out information.

Ignite your heart and soul with Sara Troy and her guest Christina Hill with Athella, on-air from October 29th Being alone and ok with oneself, the practice of solidarity, and keeping oneself aligned while in the midst of others (esp. men and wild egos!) When I am whole, healthy, and complete within, then my outer world is a mirror reflection of that inner peace and acceptance. I accept and love myself, my mind and body are healthy and happy, and I am my own best friend. I compassionately observe my thoughts, and I lovingly turn my total attention to the present moment whenever I catch myself drifting off to the past or future in my mind. I now create a loving reality within, and am open to receiving love on all levels without! https://selfdiscoverymedia.com/2019/10/28/ca19-43-being-alone-and-ok-with-oneself-with-christina-hill/

Identity Crisis - Ephesians 1:15-23: Prayer. It's a bit of a complicated reality for many of us at times in our lives. What is prayer? Why pray? What do we pray for? Does it even matter if we do pray? Paul gives us an incredible template in the later part of Ephesians 1 that gives us both pattern and passion for this dimension of our spiritual journey. I hope to be able to both alleviate some confusion and elevate the wonders related to this core practice in our walk with God. At least, I hope the Holy Spirit will do that for each of us this weekend! Much grace to you as we gather to thank Jesus for slightly warmer temperatures this weekend! Bless you!

Are good actions commanded by God because they are good? Or are good actions good because God commands them? We discuss Euthyphro’s Dilemma, the apologists’ favored “third horn” solution, and revisit the Problem of Holiness. … CA Patreon Follow us on Facebook and Twitter Contact: emersongreen@protonmail.com Emerson’s Blog Rate the show on iTunes; it’s objectively … Continue reading CA19 The Euthyphro Dilemma →

Beim kolorektalen Karzinom treten Biomarker zunehmend in den Fokus. Ziel muss daher die Etablierung von effektiven Markern sein, um den Patienten eine möglichst effektive, auf das Individuum zugeschnittene Diagnostik und Therapie anbieten zu können. In unserer Studie zum kolorektalen Karzinom sind nach Ausschlusskriterien n=108 Patienten mit Primärtumoren und n=59 Patienten mit Lebermetastasen vom KRK in die statistische Analyse eingegangen. Aus postoperativ entnommenem, N2-schockgefrorenem Gewebe wurde ein Biomarker-Profil aus molekulargenetischen und immun-histologischen Markern erstellt. Genetische Mutationen auf dem KRas- und BRaf-Gen wurden mittels Mikrodissektion/PCR/Pyrosequenzierung detektiert und mittels immunhistochemischer Färbungen die Moleküle EGF-R, Her2/neu, IGF1-R, c-Met, CD44v6, Ki67, CD45 und HLA-DR analysiert. Die statistische Analyse erfolgte univariat mittels Chi-Quadrat-Test, T-Test, Mann-Whitney-U-Test und Kruskal-Wallis-Test. Überlebensanalysen erfolgten mittels Kaplan-Meier-Schätzer und Cox-Regressionsanalyse. Hierbei ergaben sich in der univariaten Analyse zwischen den einzelnen Parametern der Primärtumoren folgende statistisch signifikante Korrelationen: Eine Mutation/der Wildtyp im KRas-Gen korrelierte mit dem L-Stadium, einer Mutation/der Wildtyp im BRaf-Gen und IGF1-R (p=0,007; 0,003; 0,034). Der um die Mutation G13D erweiterte KRas Wild-typ bzw. mutiert (ohne G13D) korrelierte hierunter mit dem L-Stadium, der Histologie, sowie ebenfalls mit BRaf (p=0,038; 0,039; 0,011). Eine Mutation im BRaf-Gen (Exon 15) war mit dem Geschlecht, der Lokalisation und dem Grading des Primärtumors signifikant verbunden (p=0,042; 0,003; 0,002). Der EGF-R korrelierte mit der Lokalisation, dem Grading, dem L-Stadium und CD44v6-Positivität (p=0,031, 0,020, 0,006, 0,021). Bei Her2/neu fand sich für das Geschlecht, die Lokalisation, CD45 und für HLA-DR eine Ver-knüpfung (p=0,005, 0,021, 0,032, 0,006). Zudem konnte ein Zusammenhang zwischen Her2/neu (Score) und dem Geschlecht (p=0,009) sowie der Tumorlokalisation (p=0,010) nachgewiesen werden. Für c-Met und IGF1-R (p=0,021) und für IGF1-R mit der Lokalisation des Primarius (p=0,027) bestand eine positive Korrelation. Des Weiteren korrelierten CD45 mit HLA-DR (p=0,046) und Ki67 mit dem Alter der Patienten (p=0,015). Hinsichtlich der Lebermetastasen konnte eine Verbindung von EGF-R mit der Histologie, mit IGF1-R und c-Met (p=0,046; 0,004; 0,007) nachgewiesen werden. Zudem konnte für c-Met und der Tumor-größe, dem löslichen präoperativen Tumormarker CA19-9 und CD44v6 (p=0,004; 0,003; 0,044) eine positive Korrelation nachgewiesen werden. HLA-DR und der BMI wiesen einen statistisch signifikanten Wert (p=0,022) auf und für Ki67 und CD44v6 bestand ebenfalls eine signifikante Verbindung (p=0,007). Ki67 und das Grading (p=0,017) sowie Her2/neu (Score) und die Histologie der Lebermetastasen (p=0,018) wiesen ebenfalls Signifikanz auf. Für das Gesamtüberleben im Kollektiv der Primärtumoren konnte im Kaplan-Meier-Schätzer ein Zusammenhang von N-Stadium (p

Diese dreiarmige Phase-II-Studie ist die erste prospektive randomisierte Studie, die drei verschiedene Zweifach-Kombinations-Chemotherapien beim fortgeschrittenen duktalen Adenokarzinom des Pankreas vergleicht. Die Daten zum Zeitpunkt der Auswertung sind insbesondere bezüglich dem primären Zielkriterium Progressfreies Überleben (PFS) und dem sekundären Zielkriterium Gesamtüberleben (OS) und bezüglich der Auswertungen der Nebenwirkungen als reif anzusehen. Die Ausgangskriterien und die Strata sind relativ gut über die drei Arme verteilt. Im Median sind die Patienten 63 Jahre alt. Bei der überwiegenden Mehrheit der Patienten (82%) liegt ein metastasiertes Stadium vor, 68% hatten nachgewiesene Metastasen in der Leber. Ein Großteil der Patienten hat bei Einschluss einen ordentlichen KPS (84% mit KPS ≥80%) aufgewiesen. Keine der drei Kombinationen hat den primären Endpunkt einer Rate des PFS nach 3 Monaten von über 70% erreicht. Das PFS nach 3 Monaten lag aber für die randomisierten Patienten insgesamt mit 60% (95%-KI: 54% - 68%) über dem unter einer Gemcitabin- Therapie zu erwartenden PFS nach 3 Monaten von 50%. Hier schneidet im Trend der CAPGEM-Arm mit 64% (95%-KI: 53% - 77%) und der mGEMOX-Arm mit 60% (95%- KI: 49% - 74%) etwas besser ab als der CAPOX-Arm mit 51% (95%-KI 40% - 65%). Der Median des PFS als sekundäres Zielkriterium wurde im CAPGEM-Arm mit 5,7 Monaten geschätzt. Dies war im Trend besser als unter CAPOX (p=0,42) mit 4,2 Monaten und unter mGEMOX (p = 0,47) mit 3,9 Monaten. Die Gesamtansprechrate (ORR) als weiterer sekundärer Endpunkt war ebenfalls im CAPGEM-Arm mit 25% im Trend besser als die mit jeweils 13% identischen Ergebnisse im CAPOX-Arm und mGEMOX-Arm (jeweils p = 0,11). Beim sekundären Zielkriterium medianes Gesamt-Überleben (OS) besteht zwischen den Behandlungsarmen kein statistisch signifikanter Unterschied, es erreichte 8,1 Monate für CAPOX, 9,0 Monate für CAPGEM und 6,9 Monate für mGEMOX. Insgesamt ist die Effektivität der drei Therapiearme bezüglich der Zielkriterien PFS nach 3 Monaten und OS statistisch nicht signifikant unterschiedlich. Bei den paarweisen Vergleichen ergibt sich aber ein Trend im PFS, in der objektiven Remissionsrate und im medianen Gesamtüberleben (OS) zuungunsten des mGEMOX-Arms. Bei Betrachtung der Sicherheit sind die Häufigkeiten von Grad-3- oder Grad-4-Nebenwirkungen insgesamt mäßig. Alle drei Therapiemodalitäten konnten bei vertretbarer Verträglichkeit gegeben werden. Es konnten jedoch signifikante Unterschiede im Spektrum der Nebenwirkungen beobachtet werden. Die hämatologische Toxizität ist signifikant am geringsten im CAPOX-Arm (p

Background: Pancreatic cancer is the fourth most common cause of cancer related death in Western countries. Advantages in surgical techniques, radiation and chemotherapy had almost no impact on the long term survival of affected patients. Therefore, the need for better treatment strategies is urgent. HER2, a receptor tyrosine kinase of the EGFR family, involved in signal transduction pathways leading to cell growth and differentiation is overexpressed in a number of cancers, including breast and pancreatic cancer. While in breast cancer HER2 has already been successfully used as a treatment target, there are only limited data evaluating the effects of inhibiting HER2 tyrosine kinases in patients with pancreatic cancer. Methods: Here we report the design of a prospective, non-randomized multi-centered Phase II clinical study evaluating the effects of the Fluoropyrimidine-carbamate Capecitabine (Xeloda (R)) and the monoclonal anti-HER2 antibody Trastuzumab (Herceptin (R)) in patients with non-resectable, HER2 overexpressing pancreatic cancer. Patients eligible for the study will receive Trastuzumab infusions on day 1, 8 and 15 concomitant to the oral intake of Capecitabine from day 1 to day 14 of each three week cylce. Cycles will be repeated until tumor progression. A total of 37 patients will be enrolled with an interim analysis after 23 patients. Discussion: Primary end point of the study is to determine the progression free survival after 12 weeks of bimodal treatment with the chemotherapeutic agent Capecitabine and the anti-HER2 antibody Trastuzumab. Secondary end points include patient's survival, toxicity analysis, quality of life, the correlation of HER2 overexpression and clinical response to Trastuzumab treatment and, finally, the correlation of CA19-9 plasma levels and progression free intervals.

Background: Gastrointestinal cancer antigen CA19-9 is known as a valuable marker for the management of patients with pancreatic cancer. Methods: The analytical and clinical performance of the Access(R) GI Monitor assay (Beckman Coulter) was evaluated on the UniCel(R) Dxl 800 Immunoassay System at five different European sites and compared with a reference method, defined as CA19-9 on the Elecsys System (Roche Diagnostics). Results: Total imprecision (%CV) of the GI Monitor ranged between 3.4% and 7.7%, and inter-laboratory reproducibility between 3.6% and 4.0%. Linearity upon dilution showed a mean recovery of 97.4% (SD+7.2%). Endogenous interferents had no influence on GI Monitor levels (mean recoveries: hemoglobin 103%, bilirubin 106%, triglycerides 106%). There was no high-dose hook effect up to 115,000 kU/L. Clinical performance investigated in sera from 1811 individuals showed a good correlation between the Access' GI Monitor and Elecsys CA19-9 (R = 0.959, slope = 1.004, intercept +0.17). GI Monitor serum levels were low in healthy individuals (n = 267, median = 6.0 kU/L, 95th percentile = 23.1 kU/L), higher in individuals with various benign diseases (n = 550, medians = 5.8-13.4 kU/L, 95th percentiles = 30.1-195.5 kU/L) and even higher in individuals suffering from various cancers (n = 995, medians = 8.4-233.8 kU/L, 95th percentiles = 53.7-13,902 kU/L). Optimal diagnostic accuracy for cancer detection against the relevant benign control group by the GI Monitor was found for pancreatic cancer {[}area under the curve (AUC) 0.83]. Results for the reference CA19-9 assay were comparable (AUC 0.85). Conclusions: The Access(R) GI Monitor provides very good methodological characteristics and demonstrates an excellent analytical and clinical correlation with the Elecsys CA19-9. The GI Monitor shows the best diagnostic accuracy in pancreatic cancer. Our results also suggest a clinical value of the GI Monitor in other cancers.

Objective: To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients. Methods: Within a prospective single-center study, Cap was offered to patients who had already received at least 1 previous treatment regimen containing full-dose Gem (as a single agent, as part of a combination chemotherapy regimen or sequentially within a chemoradiotherapy protocol). Cap was administered orally at a dose of 1,250 mg/m(2) twice daily for 14 days followed by 7 days of rest. Study endpoints were objective tumor response rate by imaging criteria (according to RECIST), carbohydrate antigen 19-9 (CA19-9) tumor marker response, time to progression, overall survival and toxicity. Results: A median of 3 treatment cycles (range 1-36) was given to 39 patients. After a median follow-up of 6.6 months, 27 patients were evaluable for response: no complete or partial responses were observed, but 15 patients (39%) had stable disease. A CA19-9 reduction of >20% after 2 cycles of Cap was documented in 6 patients (15%). Median time to progression was 2.3 months (range 0.5-45.1) and median overall survival (since start of Cap treatment) was 7.6 months (range 0.7-45.1). Predominant grade 2 and 3 toxicities (per patient analysis) were hand-foot syndrome 28% (13% grade 3); anemia 23%; leg edema 15%; diarrhea 13%; nausea/vomiting 10%, and leukocytopenia 10%. Conclusion: Single-agent Cap is a safe treatment option for Gem-pretreated patients with advanced PC. Further evaluation of Cap in controlled clinical trials of Gem-pretreated patients with advanced PC is recommended. Copyright (C) 2008 S. Karger AG, Basel.